Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide

Journal of the National Cancer Institute

Volumn 90, Issue 14, 1998, Pages 1087-1094

  Ciardiello, Fortunato ^a   Caputo, Rosa ^a   Bianco, Roberto ^a   Damiano, Vincenzo ^a   Pomatico, Grazia ^a   Pepe, Stefano ^a   Bianco, A Raffaele ^a   Agrawal, Sudhir ^b   Mendelsohn, John ^c   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b HYBRIDON INC   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE HYB 190; CETUXIMAB; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CANCER; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUDE MOUSE; XENOGRAFT;

EID: 0032527802     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.14.1087     Document Type: Article

References (53)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
2. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
3. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11: 1368-75.
4. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interaction in vitro. J Clin Oncol 1995;13:1950-7.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
6. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor α. Cancer Res 1992;52:3335-9.
7. Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WD, Fair WR. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 1989;49:3407-11.
8. Uhlman DL, Nguyen P, Manivel JC, et al. Epidermal growth factor receptor and transforming growth factor α expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1995;1:913-20.
9. Baselga J, Mendelsohn J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J Mammary Gland Biol Neoplasia 1997;2:165-74.
10. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984;259: 7755-60.
11. Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 1989;49:3482-8.
12. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein. Cancer Res 1994;54:4703-9.
13. Kirk J, Carmichael J, Stratford U, Harris AL. Selective toxicity of TGF-α-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF. Br J Cancer 1994;69:988-94.
14. Lorimer IAJ, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res 1995;1:859-64.
15. Schmidt M, Wels W. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα. Br J Cancer 1996;74:853-62.
16. Buchdunger E, Mett H, Trinks U, Regenass U, Muller M, Meyer T, et al. 4,5-bis(4-Fluoroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin Cancer Res 1995;1:813-21.
17. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605-11.
18. Modjtahedi H, Eccles S, Box G, Styles J, Dean C. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 1993;67: 254-61.
19. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-7.
20. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al. Phase I and imaging trial of indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97-104.
21. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
22. Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, et al. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc ASCO 1996;15:1381.
23. Slavin SF, Kelly WK, Cohen R, Cooper M, Malone T, Weingard K, et al. Epidermal growth factor receptor monoclonal antibody C225 and doxorubicin in androgen-independent prostate cancer: results of a phase Ib/IIa study. Proc ASCO 1997;16:1108.
24. Falcey J, Pfister D, Cohen R, Cooper M, Bowden C, Burtness B, et al. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas. Proc ASCO 1997;16:1364.
25. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation and suppression of malignancy: new approaches to therapy. Cancer Res 1990;50:7093-100.
26. Tortora G, Pepe S, Bianco C, Baldassarre G, Budillon A, Clair T, et al. The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 1994;9:3233-40.
27. Pepe S, Ruggiero A, Tortora G, Ciardiello F, Garbi C, Yokozaki H, et al. Flow-cytometric detection of the RIα subunit of type I cAMP-dependent protein kinase in human cells. Cytometry 1994;15:73-9.
28. Tortora G, Pepe S, Cirafici AM, Ciardiello F, Porcellini A, Clair T, et al. Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cyclic AMP-dependent protein kinase. Cell Growth Differ 1993;4:359-65.
29. Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, et al. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 1997; 14:923-8.
30. Tortora G, Ciardiello F, Ally S, Clair T, Salomon DS, Cho-Chung YS. Site-selective 8-chloroadenosine 3′,5′ monophosphate inhibits transformation and transforming growth factor α production in Ki-ras-transformed rat fibroblasts. FEES Lett 1989;242:363-7.
31. Ciardiello F, Tortora G, Kim N, Clair T, Ally S, Salomon DS, Cho-Chung YS. 8-Chloro-cAMP inhibits transforming growth factor α transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. J Biol Chem 1990;265:1016-20.
32. Miller WR, Watson DM, Jack W, Chetty U, Elton RA. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat 1993;26: 89-94.
33. Cho-Chung YS, Clair T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases. Pharmacol Ther 1993;60:265-88.
34. Fossberg TM, Doskeland SO, Ueland PM. Protein kinases in human renal cell carcinoma and renal cortex. A comparison of isozyme distribution and of responsiveness to adenosine 3′,5′-cyclic monophosphate. Arch Biochem Biophys 1978;189:272-81.
35. Tagliaferri P, Katsaros D, Clair T, Ally S, Tortora G, Neckers L, et al. Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cAMP analogues. Cancer Res 1988;48:1642-50.
36. Ally S, Clair T, Katsaros D, Tortora G, Yokozaki H, Finch RA, et al. Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate. Cancer Res 1989;49:5650-5.
37. Rohlff C, Clair T, Cho-Chung YS. 8-Cl-cAMP induces truncation and down-regulation of the RIα subunit and up-regulation of the RIIβ subunit of cAMP-dependent protein kinase leading to type II holoenzymedependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 1993;268:5774-82.
38. Ciardiello F, Pepe S, Bianco C, Baldassarre G, Ruggiero A, Bianco C, et al. Down-regulation of RIα subunit of the cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int J Cancer 1993;53:438-43.
39. Tortora G, Ciardiello F, Pepe S, Tagliaferri P, Ruggiero A, Bianco C, et al. Phase I clinical study with 8-Chloro-cAMP and evaluation of immunological effects in cancer patients. Clin Cancer Res 1995;1:377-84.
40. Tortora G, Yokozaki H, Pepe S, Clair T, Cho-Chung YS. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 1991; 88:2011-5.
41. Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage S, Miki K, et al. An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 1993;53:868-72.
42. Nesterova M, Cho-Chung YS. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med 1995;1:528-33.
43. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996;14:376-87.
44. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, et al. Mixedbackbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 1997;94: 2620-5.
45. Tortora G, Caputo R, Damiano V, Bianco R, Pepe S, Bianco AR, et al. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci U S A 1997;94:12586-91.
46. Ciardiello F, Damiano V, Bianco C, di Isernia, Ruggiero A, Caraglia M, et al. Cooperative antiproliferative effects of 8-Chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. Clin Cancer Res 1995;1:161-7.
47. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996;88: 1770-6.
48. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
49. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995; 95:1897-905.
50. Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat Med 1995;1:309-20.
51. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, et al. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 1997;89:1505-15.
52. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1992;53:4637-42.
53. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J. Antitumor effects of doxorubicin in combination with antiepidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-33.